Zhe Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhe Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bing Liu
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China
1 shared publication - Bo Jiang
Department of Ultrasound, the First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Rd, Haidian District, Beijing 100853, China
1 shared publication - Lianhua Zhu
Department of Ultrasound, the First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Rd, Haidian District, Beijing 100853, China
1 shared publication - Shichun Lu
Medical School of Chinese PLA, Beijing, China; Faculty of Hepato-Pancreato-Biliary Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing, China; Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China; Key Laboratory of Digital Hepatobiliary Surgery, PLA, Beijing, China
1 shared publication Wenwen Zhang
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China
1 shared publication- Xiang Fei
Department of Ultrasound, The First Medical Center, Chinese PLA General Hospital, Beijing, China
1 shared publication
Latest Publications
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251698
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy
Contrast-enhanced US demonstrated a sensitivity and area under the receiver operating characteristic curve noninferior to contrast-enhanced MRI in the detection of residual hepatocellular carcinoma after lenvatinib and anti–programmed cell death protein-1 antibody therapy.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251698
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy
Contrast-enhanced US demonstrated a sensitivity and area under the receiver operating characteristic curve noninferior to contrast-enhanced MRI in the detection of residual hepatocellular carcinoma after lenvatinib and anti–programmed cell death protein-1 antibody therapy.